Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 639-644, 2019.
Artigo
em Chinês
| WPRIM
| ID: wpr-775579
ABSTRACT
Immune checkpoint inhibitors (ICIs) represent a major breakthrough in cancer therapy. Immune-related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Dermatologic toxicities appear to be one of the most prevalent irAEs. The most common symptoms are maculopapular rash and pruritus. Serious dermatologic AEs, including Stevens-Johnson syndrome and toxic epidermal necrolysis, are rare. In this review, we summarized guidelines of management of immunotherapy-related toxicities and case reports, and proposed treatment recommendation.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Guia de Prática Clínica
Idioma:
Chinês
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS